* Note: Prices are in Million (M) USD.
Description:
ImmunityBio, Inc. is an innovative immunotherapy company dedicated to developing groundbreaking treatments that harness the power of memory T-cells for the fight against various cancers. The company's proprietary cancer vaccine represents a paradigm shift in oncology, aiming to optimize therapeutic efficacy while reducing dependence on high-dose chemotherapy. Through its cutting-edge biotechnology platform, ImmunityBio is poised to redefine cancer treatment paradigms, enhance patient outcomes, and establish itself as a leader in the rapidly changing landscape of cancer therapeutics.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $60 M
Debt : $508 M
EBITDA : $-233 M
Net Debt (Debt - Cash): $448 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 12 overlapping fiscal years (max 20).Average Free Cash Flow: $-174 M
Average Revenue: $2 M
Revenue Converted To Free Cash Flow (%): -9,961.4%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $15 M
Revenue 5 Years Ago (2019-12-31): $2 M
Total Growth over 5 Years: 569.6%
5-Year Revenue CAGR (Historical): 46.3%
Forward 5-Year CAGR (Tapered): 23.1%
Since historical Revenue CAGR is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $700 M
Share Count 5 Years Ago (2020-12-31): $383 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-0.26
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-0.26
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 6 valid ROE years (max 20).Average ROE: -60.2%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $2.09
52-Week Low: $1.83
Threshold Price (15% Above 52-Week Low): $2.10
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $1,999 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 16 points to above Immunitybio Inc (IBRX) stock.
Fair Value PE 12, Industry Based PE 15, Growth Based PE 23.14, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 4 values, average assigned is 17.15. The fair value of Immunitybio Inc (IBRX) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
